EP0715516A1 - Oral compositions of h 2?-antagonists - Google Patents

Oral compositions of h 2?-antagonists

Info

Publication number
EP0715516A1
EP0715516A1 EP94925883A EP94925883A EP0715516A1 EP 0715516 A1 EP0715516 A1 EP 0715516A1 EP 94925883 A EP94925883 A EP 94925883A EP 94925883 A EP94925883 A EP 94925883A EP 0715516 A1 EP0715516 A1 EP 0715516A1
Authority
EP
European Patent Office
Prior art keywords
composition
calcium carbonate
antagonist
weight
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94925883A
Other languages
German (de)
French (fr)
Inventor
Henry C. Caldwell
Ashok J. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AAIPharma Inc
Original Assignee
Applied Analytical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Analytical Industries Inc filed Critical Applied Analytical Industries Inc
Publication of EP0715516A1 publication Critical patent/EP0715516A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Definitions

  • This invention relates to pharmaceutically elegant compositions of therapeutic compounds having H 2 -antagonist activity especially adapted for convenient oral administration.
  • U.S. Patent No. 4,719,228 discloses the use of selected synthetic silicas to form free flowing powder products of a number of therapeutic classes of drugs including antiulcer drugs. No reference to H 2 - antagonists is made here.
  • This invention relates to pharmaceutical oral compositions containing one or more H 2 -antagonist drugs. These compositions do not exhibit a bitter taste in the mouth and distribute the active ingredient substantially in the gastrointestinal tract.
  • the composition contains, as essential ingredients, an H 2 -antagonist - magnesium aluminum silicate complex and calcium carbonate.
  • the dosage unit form is any which would normally expose the bitter H 2 -antagonist to the taste of the patient but is preferably a chewable tablet. For larger doses, it may be a sachet, lozenge or packaged flavored granules. Best Mode for Carrying Out the Invention
  • H 2 -compounds are preferably administered orally.
  • the oral product forms of these compounds are capsules or coated tablets. Certain segments of the patient population prefer more easily ingested product forms. This is most evident in the over- the-counter market.
  • One of the most useful of such product forms is the chewable or frangible tablet, lozenge or troche. Examples of the preparation of chewable products are found in U.S. Patent No. 4,711,774 which is cited in the Background section above.
  • H 2 -antagonists form tasteless adsorbates with magnesium aluminum silicate readily and substantially completely.
  • the addition of a selected quantity of calcium carbonate dramatically improves the release of active ingredient from the silicate adsorbate, but does not cause overt side effects such as substantial release of carbon dioxide by effervescence. This is so especially when the formulations are prepared with acid addition salts of the biologically active ingredients or with added solid acid formulation aids such as the fruit acids, for example citric acid, within the granules in the formulation process.
  • the complex between the active biological ingredient and the magnesium aluminum silicate is usually formed in situ, that is, during the formulation of the dosage unit composition.
  • composition of this invention is in its preferred form a chewable tablet comprised essentially of a therapeutically effective but non-toxic dosage unit quantity of an H 2 -antagonist complex formed with a magnesium aluminum silicate, which complex is usually prepared during formulation, and a quantity of calcium carbonate.
  • the magnesium aluminum silicate which is the support component of this combination is preferably the commercial product known as "Veegum” supplied by R.T. Vanderbilt Company, Inc. Analysis of the commercial product is carried out as oxide contents. No control of the particle size of the commercial grade of product has been found necessary. Comprehensive descriptions of the product are in the Zentner-Denick patents noted above.
  • the exact quantity of the silicate support is not critical to the invention as long as enough is present to completely adsorb the drug component in situ. An excess is most convenient and preferred with ranges of from 10 - 30% by weight of the dosage unit.
  • Magnesium aluminum silicates have been used in the literature to delay the release of other active ingredients in time release products when used in excess. This is in contrast to the present invention which affords good quick release of drug.
  • the H 2 -antagonist in either the base or its acid addition salt form as appropriate, is preferably selected from those approved for use in either the prescription or over-the-counter pharmaceutical markets.
  • the dosage units will contain either a full therapeutic dose, or a partial dose for a subject in need of relief so that from 1-5 units may be administered per day to obtain satisfactory treatment of symptoms.
  • the non-prescription products usually contain a lower dose, often about half the quantity.
  • active H 2 -antagonists examples include cimetidine (300 mg) , nizatidine (150 mg) , roxatidine (acetate), famotidine (20 mg) , ranitidine (150 mg) , tiotidine, lamtidine, mifentidine, zaltidine, KV-1257 or loxtidine (Handbook Exp. Pharmacol. 97 573-748 (1991), "Histamine and Histamine Antagonists”) .
  • the daily dose range of active ingredient is a nontoxic but H 2 -antagonist effective quantity and may be chosen from 40 to 1600 mg.
  • the dosage units may range from 10 - 800 mg of active ingredient depending on the known individual activity and market of the H 2 -antagonist drug.
  • the units are administered from 1-5 times daily orally to a patient in need of H 2 -antagonist treatment.
  • the H 2 -antagonist may be present either as the base if appropriate or as a salt thereof with a nontoxic, pharmaceutically acceptable acid.
  • the dose and the form which is commercially available is conveniently used.
  • the H 2 -antagonist-silicate adsorbate is formed substantially completely during formulation despite which base or salt form of the active H 2 -antagonist is selected.
  • the calcium carbonate is selected from the range of 75-500 mg per dosage unit.
  • the calcium carbonate supplemented product is preferably used in non-toxic quantities in up to 5 units per day.
  • a general range of calcium carbonate content of the oral product is from about 1-35% by weight of the chewable tablet products. For example, for a 1500 mg. tablet as much as 500 mg. of calcium carbonate may be present. Overt evolution of carbon dioxide has not been observed when the compositions contact water.
  • One skilled in the art will recognize that the size of chewable tablets may be larger than that of normal compressed tablets.
  • composition of this invention may be optionally used in addition to the essential ingredients described above.
  • these are bulking agents, flavoring agents. granulating agents, buffering agents, coloring agents, preservatives, confectioneries and the like. Reference may be made to U.S. Patent No. 4,711,774 for more specific formulation information.
  • Especially useful optional ingredients are the solid fruit acids such as citric, malic or tartaric acids in up to 3% by weight for good stability and palatability of the chewable tablet as well as xylitol or mannitol as a sweetening-bulking agent in up to 70% by weight.
  • Citric acid as well as xylitol are particularly advantageous since each contributes unexpectedly well to the palatability of the chewable tablets.
  • quantity of calcium carbonate and acid should be selected to insure good release, but not to cause overt carbon dioxide evolution. The absence of the acid component gives acceptable products as well.
  • the chewable tablets of this invention are prepared by mixing the H 2 -antagonist compound with magnesium aluminum silicate in a weight ratio chosen from the range of 1 to 1 down to 1 to 10 with an optional sweetening agent in a mixer, adding water to form the complex and granulate.
  • the dried and milled granules are mixed with the calcium carbonate, bulking-sweetening agents and tabletting aids then compressed into tablets.
  • the chewable pharmaceutical products are taken by the subject in need of H 2 -antagonist treatment orally from 1 to 5 times daily as required to satisfy the acceptable daily dosage regimen of active ingredients. It should be particularly noted that the antacid component of the chewable tablet may also contribute to lowering the acid content of the gastrointestinal tract.
  • the dosage units should be prepared and used with this in mind.
  • the method of analysis used and detailed hereafter is the ultraviolet dissolution method as reported in the USP XXII (p. 3074) . Usually times for pulling samples were 15, 30, 45, 60 minutes. The ultraviolet wave lengths vary, of course, with the active ingredient. Cimetidine is at 218 nm. Nizatidine and ranitidine are at 314 nm. Famotidine is at 265 nm.
  • an acid agent such as a fruit acid, for example, citric, malic or tartaric acid in the formulation, this is added to the manufacturing process at Step 1 before the granulation • process, usually at about 1.5%.
  • Example 3 The percentage of cimetidine dissolved in water using the U.S.P. method II at 50 RPM to 60 minutes from granules with added citric acid (3%), calcium carbonate (75 mg) and without calcium carbonate. Time Without CaC0 3 With CaC0 3
  • Example 5 Nizatidine with and without calcium carbonate compared at 0 time and 1 month stability (40°; 75%RH) , citric acid (1.5%) added to all samples.
  • Nizatidine granules compared in water with tablet with 1.5% citric acid and tablet with 1.5% of citric acid and 37.5 mg of calcium carbonate.
  • Example 1 The process of Example 1 is used with 25% by weight of magnesium aluminum silicate, 5% of nizatidine, 0.25% of sodium saccharin and 1.2% of citric acid. The granules, before tabletting, were compared with the tabletted product and with the chewable tablet with 5% of calcium carbonate.

Abstract

Chewable tablets of H2-antagonists which are tasteless in the mouth, but give good release of active ingredients are prepared using calcium carbonate and a supportive magnesium aluminum silicate. Also contributing to the formulation are such non-essentials as xylitol and fruit acids.

Description

Description ORAL COMPOSITIONS OF H2 - ANTAGONISTS •
This invention relates to pharmaceutically elegant compositions of therapeutic compounds having H2-antagonist activity especially adapted for convenient oral administration.
Background of the Invention
Magnesium aluminum silicates have been known in the pharmaceutical art to be useful to mask the bitter taste of a variety of medicinal agents. U.S. Patent No. 3,140,978 (M. R. Zentner) , together with related patents such as 3,248,290, 3,337,402, 3,337,403, as well as U.S. Patent No. 4,711,774 (J. Denick Jr.), together with 4,716,033, 4,717,565, 4,758,424, 4,758,425 and 4,761,274, describe the adsorption of medications of many therapeutic classes onto magnesium aluminum silicates as well as the suspensions, granulations, lozenges, chewable tablets and the like prepared from the resulting complexes using standard formulation methods. None of these mention the use of H2-antagonists as the active therapeutic agent.
Other specific applications of magnesium aluminum silicates to formulation procedures are disclosed in U.S. Patent Nos. 3,432,593 (M. Shepard) , 3,567,819 and 4,753,800. These also are of a specific aim and are believed cumulative as well to the two basic references of Zentner and Denick mentioned above.
U.S. Patent No. 4,719,228 (D. Rawlins) discloses the use of selected synthetic silicas to form free flowing powder products of a number of therapeutic classes of drugs including antiulcer drugs. No reference to H2- antagonists is made here.
The scientific literature contains studies of the use of silicate clays in formulating various drugs of different chemical types and the nature of the binding forces involved. In general, the release of the active ingredient from such formulations is uncertain but is often retarded by clay admixture, J.W. McGinity et al., J. Pharm. Sc. 55, 896; J.T. Carstensen et al., J. Pharm. Sc. 60 733. Certain electrolytes such as sodium and magnesium chloride are reported to facilitate the release of antibiotics from clay adsorbates, J.W. McGinity et al., J. Pharm. Sc. ^4, 1567.
An effervescent tablet containing ranitidine as the active H2-antagonist agent has been reported. This pharmaceutical form, which contains sodium acid pyrophosphate, an acid salt, demonstrated substantial reduced bioavailability of the active ingredient (54%) . K.M. Koch et al., Pharm. Res. 10 1027 (1993).
U.S. Patent No. 5,219,563 (S.J. Douglas) reports adsorbates of ranitidine on synthetic ion exchange resin.
Disclosure of the Invention
This invention relates to pharmaceutical oral compositions containing one or more H2-antagonist drugs. These compositions do not exhibit a bitter taste in the mouth and distribute the active ingredient substantially in the gastrointestinal tract. The composition contains, as essential ingredients, an H2-antagonist - magnesium aluminum silicate complex and calcium carbonate. The dosage unit form is any which would normally expose the bitter H2-antagonist to the taste of the patient but is preferably a chewable tablet. For larger doses, it may be a sachet, lozenge or packaged flavored granules. Best Mode for Carrying Out the Invention
Most drugs which have H2-antagonist activity, and are thereby useful for treating various gastrointestinal disorders such as ulcers, dyspepsia or gastrointestinal reflux indications, have a bitter taste. The H2-compounds are preferably administered orally. For the usual prescription use, the oral product forms of these compounds are capsules or coated tablets. Certain segments of the patient population prefer more easily ingested product forms. This is most evident in the over- the-counter market. One of the most useful of such product forms is the chewable or frangible tablet, lozenge or troche. Examples of the preparation of chewable products are found in U.S. Patent No. 4,711,774 which is cited in the Background section above.
As stated above, the pharmaceutical art has long recognized that the natural or processed magnesium aluminum silicates adsorb a wide variety of medicaments to some degree. Natural clays such as attapulgite and montmorillonite have been used, but, in our hands, these are not as satisfactory for use with H2-antagonists as are the processed silicates known by the trade name "Veegum". The latter are also described in detail in the above cited prior art and are widely accepted for pharmaceutical use.
The literature describes the nature of silicate-drug binding and the uncertain release of various active ingredients from the adsorbate complex. Mechanical and chemical methods of increasing the reliability of release are many but, more often than not, unsuccessful. Ionic additives such as the halide salts have not been successful due to the side effects due to large ingestions of such salts.
This invention is based on several discoveries which are unique with the use of H2-antagonists. Firstly, the H2-antagonist compounds form tasteless adsorbates with magnesium aluminum silicate readily and substantially completely. Secondly, the addition of a selected quantity of calcium carbonate dramatically improves the release of active ingredient from the silicate adsorbate, but does not cause overt side effects such as substantial release of carbon dioxide by effervescence. This is so especially when the formulations are prepared with acid addition salts of the biologically active ingredients or with added solid acid formulation aids such as the fruit acids, for example citric acid, within the granules in the formulation process. The complex between the active biological ingredient and the magnesium aluminum silicate is usually formed in situ, that is, during the formulation of the dosage unit composition.
The composition of this invention, therefore, is in its preferred form a chewable tablet comprised essentially of a therapeutically effective but non-toxic dosage unit quantity of an H2-antagonist complex formed with a magnesium aluminum silicate, which complex is usually prepared during formulation, and a quantity of calcium carbonate.
The magnesium aluminum silicate which is the support component of this combination is preferably the commercial product known as "Veegum" supplied by R.T. Vanderbilt Company, Inc. Analysis of the commercial product is carried out as oxide contents. No control of the particle size of the commercial grade of product has been found necessary. Comprehensive descriptions of the product are in the Zentner-Denick patents noted above.
The exact quantity of the silicate support is not critical to the invention as long as enough is present to completely adsorb the drug component in situ. An excess is most convenient and preferred with ranges of from 10 - 30% by weight of the dosage unit. Magnesium aluminum silicates have been used in the literature to delay the release of other active ingredients in time release products when used in excess. This is in contrast to the present invention which affords good quick release of drug.
The H2-antagonist, in either the base or its acid addition salt form as appropriate, is preferably selected from those approved for use in either the prescription or over-the-counter pharmaceutical markets. The dosage units will contain either a full therapeutic dose, or a partial dose for a subject in need of relief so that from 1-5 units may be administered per day to obtain satisfactory treatment of symptoms. The non-prescription products usually contain a lower dose, often about half the quantity. Examples of active H2-antagonists and suggested doses are cimetidine (300 mg) , nizatidine (150 mg) , roxatidine (acetate), famotidine (20 mg) , ranitidine (150 mg) , tiotidine, lamtidine, mifentidine, zaltidine, KV-1257 or loxtidine (Handbook Exp. Pharmacol. 97 573-748 (1991), "Histamine and Histamine Antagonists") .
The daily dose range of active ingredient is a nontoxic but H2-antagonist effective quantity and may be chosen from 40 to 1600 mg. The dosage units may range from 10 - 800 mg of active ingredient depending on the known individual activity and market of the H2-antagonist drug. The units are administered from 1-5 times daily orally to a patient in need of H2-antagonist treatment. The H2-antagonist may be present either as the base if appropriate or as a salt thereof with a nontoxic, pharmaceutically acceptable acid. Usually, the dose and the form which is commercially available is conveniently used. Surprisingly, the H2-antagonist-silicate adsorbate is formed substantially completely during formulation despite which base or salt form of the active H2-antagonist is selected.
Preferably, the calcium carbonate is selected from the range of 75-500 mg per dosage unit.
The calcium carbonate supplemented product is preferably used in non-toxic quantities in up to 5 units per day. A general range of calcium carbonate content of the oral product is from about 1-35% by weight of the chewable tablet products. For example, for a 1500 mg. tablet as much as 500 mg. of calcium carbonate may be present. Overt evolution of carbon dioxide has not been observed when the compositions contact water. One skilled in the art will recognize that the size of chewable tablets may be larger than that of normal compressed tablets.
A variety of other pharmaceutical additives may be optionally used in the composition of this invention in addition to the essential ingredients described above. Among these are bulking agents, flavoring agents. granulating agents, buffering agents, coloring agents, preservatives, confectioneries and the like. Reference may be made to U.S. Patent No. 4,711,774 for more specific formulation information.
Especially useful optional ingredients are the solid fruit acids such as citric, malic or tartaric acids in up to 3% by weight for good stability and palatability of the chewable tablet as well as xylitol or mannitol as a sweetening-bulking agent in up to 70% by weight. Citric acid as well as xylitol are particularly advantageous since each contributes unexpectedly well to the palatability of the chewable tablets. When such acids are used for this purpose, quantity of calcium carbonate and acid should be selected to insure good release, but not to cause overt carbon dioxide evolution. The absence of the acid component gives acceptable products as well.
The chewable tablets of this invention are prepared by mixing the H2-antagonist compound with magnesium aluminum silicate in a weight ratio chosen from the range of 1 to 1 down to 1 to 10 with an optional sweetening agent in a mixer, adding water to form the complex and granulate. The dried and milled granules are mixed with the calcium carbonate, bulking-sweetening agents and tabletting aids then compressed into tablets.
The chewable pharmaceutical products are taken by the subject in need of H2-antagonist treatment orally from 1 to 5 times daily as required to satisfy the acceptable daily dosage regimen of active ingredients. It should be particularly noted that the antacid component of the chewable tablet may also contribute to lowering the acid content of the gastrointestinal tract. The dosage units should be prepared and used with this in mind.
The method of analysis used and detailed hereafter is the ultraviolet dissolution method as reported in the USP XXII (p. 3074) . Usually times for pulling samples were 15, 30, 45, 60 minutes. The ultraviolet wave lengths vary, of course, with the active ingredient. Cimetidine is at 218 nm. Nizatidine and ranitidine are at 314 nm. Famotidine is at 265 nm.
The following embodiments of this invention are designed to illustrate and teach the specific use of the invention but not to limit its scope.
Example 1
% By Wei .ght
A B C D
Ingredients
Nizatidine USP 5 - - -
Cimetidine USP - 5 - -
Ranitidine USP - - 5 -
Famotidine USP - - - 2
Magnesium Aluminum Silicate NF 25 25 25 10
Sodium Saccharin NF .25 .25 .25 .125
Mannitol NF Q.S. Q.S. Q.S Q.S.
Xylitol NF Q.S. Q.S. Q.S. Q.S.
Colloidal Solicon Dioxide NF 1 1 1 1
Magnesium Stearate NF 1.5 1.5 1.5 1.5
Flavors Q.S. Q.S. Q.S. Q.S.
Purified water*
100 100 100 100
Remove during processing
Method of Manufacturing
1. Mix drug with magnesium aluminum silicate and sodium saccharin in a planetary mixer for five minutes.
2. Add water until a uniform granulation occurs.
3. Dry the granules.
4. Size the granules into fine powder.
5. Add mannitol, xylitol and colloidal silicon dioxide and mix for ten minutes.
6. Add magnesium stearate and mix for five minutes.
7. Compress into chewable tablets.
Example 2
% By Weight C D
Ingredients Nizatidine USP Cimetidine USP Ranitidine USP Famotidine USP - - - 2
Magnesium Aluminum Silicate NF 25 25 25 10 Calcium Carbonate 5 5 5 5 Sodium Saccharin NF .25 .25 .25 .125 Mannitol NF Q.S. Q.S. Q.S. Q.S. Xylitol NF Q.S. Q.S. Q.S. Q.S.
Colloidal Solicon Dioxide NF 1 1 1 1 Magnesium Stearate NF 1.5 1.5 1.5 1.5 Flavors Q.S. Q.S. Q.S. Q.S. Purified water*
100 100 100 100
* Remove during processing Method of Manufacturing
1. Mix drug with magnesium aluminum silicate and sodium saccharin in a planetary mixer for five minutes.
2. Add water until a uniform granulation occurs.
3. Dry the granules.
4. Size the granules into fine powder.
5. Add mannitol, .xylitol, calcium carbonate, colloidal solicon dioxide to and mix for ten minutes.
6. Add magnesium stearate and mix for five minutes.
7. Compress into chewable tablets.
If the operator wishes an acid agent such as a fruit acid, for example, citric, malic or tartaric acid in the formulation, this is added to the manufacturing process at Step 1 before the granulation •process, usually at about 1.5%.
The following comparative examples were selected to illustrate the enhanced release of active ingredient from the granules/tablets of this invention using the preparative and testing procedures described above.
Example 3 The percentage of cimetidine dissolved in water using the U.S.P. method II at 50 RPM to 60 minutes from granules with added citric acid (3%), calcium carbonate (75 mg) and without calcium carbonate. Time Without CaC03 With CaC03
15 39.9 67.5
30 44.6 74.4
45 46.9 78.8
60 48.3 82.8
75 51.6 104.3
Example 4
Ranitidine Hydrochloride (75 mg base) with Calcium Carbonate (75 mg)
Time Without CaCo3 With CaCo3 15 30.3% 44.0%
30 36.6% 51.4%
45 36.9% 53.7%
60 37.6% 56.8%
« 40.4% 63.6%
Example 5 Nizatidine with and without calcium carbonate compared at 0 time and 1 month stability (40°; 75%RH) , citric acid (1.5%) added to all samples.
Time Without CaC03 Stability With CaC03 Stability
15 30.3 30.0 77.6 45.7
30 34.8 34.5 82.3 60.3
45 36.6 37.42 84.2 67.2
60 38.8 39.4 85.3 70.0
75 42.9 44.1 94.4 90.3 Example 6
Nizatidine granules compared in water with tablet with 1.5% citric acid and tablet with 1.5% of citric acid and 37.5 mg of calcium carbonate.
Time Gran Tab (1.5% C.A.) Tab (C.A. plus CaCQ,)
0 0 0 0
30 88.8 39.1 97
Example 7
The process of Example 1 is used with 25% by weight of magnesium aluminum silicate, 5% of nizatidine, 0.25% of sodium saccharin and 1.2% of citric acid. The granules, before tabletting, were compared with the tabletted product and with the chewable tablet with 5% of calcium carbonate.
Time Gran (Without CaC03^ (With CaCO
0 0 0 0
30 37 45 92.2
60 39.2 47 93
75 47 .4 47.4 95.7

Claims

Claims
1. An oral pharmaceutical dosage unit composition for inducing H2-antagonist activity, which composition is designed for at least partial release of its H2-antagonist ingredient in the mouth, consisting essentially of from 1-35% by weight of said composition of calcium carbonate and of a complex which is prepared from a nontoxic but therapeutically effective quantity of said H2-antagonist ingredient and an excess of aluminum magnesium silicate.
2. The composition of claim 1 in which said complex is prepared during formulation of said composition and the aluminum magnesium silicate is selected from the range of 10-30% by weight of said composition.
3. The composition of claim 2 in which the composition is a chewable tablet.
4. The composition of claim 1 in which famotidine, ranitidine or cimetidine is the drug.
5. The composition of claim 1 in which nizatidine is the drug.
6. The composition of claim 1 in which xylitol or mannitol is present as a bulking -sweetening agent.
7. The composition of claim 2 in which the calcium carbonate is present in from 75 to 500 mg.
8. The composition of claim 2 in which up to 3% by weight of citric, malic or tartaric acid is present.
9. The composition of claim 8 in which 5% by weight of calcium carbonate is present.
10. The composition of claim 9 in which said active ingredient is nizatidine.
11. The composition of claim 9 in which said active ingredient is ranitidine.
EP94925883A 1993-08-17 1994-08-16 Oral compositions of h 2?-antagonists Withdrawn EP0715516A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10712693A 1993-08-17 1993-08-17
US107126 1993-08-17
US28871194A 1994-08-12 1994-08-12
US288711 1994-08-12
PCT/US1994/009204 WO1995005173A1 (en) 1993-08-17 1994-08-16 Oral compositions of h2-antagonists

Publications (1)

Publication Number Publication Date
EP0715516A1 true EP0715516A1 (en) 1996-06-12

Family

ID=26804421

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94925883A Withdrawn EP0715516A1 (en) 1993-08-17 1994-08-16 Oral compositions of h 2?-antagonists

Country Status (5)

Country Link
EP (1) EP0715516A1 (en)
JP (1) JPH09501680A (en)
AU (1) AU7565594A (en)
CA (1) CA2169735A1 (en)
WO (1) WO1995005173A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
US6537525B1 (en) * 1997-01-29 2003-03-25 Douglas H. West Medicated chewing-gum
DE10206089A1 (en) 2002-02-13 2002-08-14 Zimmer Ag bursting
WO2007108010A2 (en) * 2006-03-21 2007-09-27 Jubilant Organosys Limited Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
MX2020004744A (en) 2017-11-09 2020-08-13 11 Health And Tech Limited Ostomy monitoring system and method.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9205827A (en) * 1991-04-04 1994-06-28 Procter & Gamble Ingestible pharmaceutical compositions for treating disorders of the upper gastrointestinal tract
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9505173A1 *

Also Published As

Publication number Publication date
CA2169735A1 (en) 1995-02-23
JPH09501680A (en) 1997-02-18
AU7565594A (en) 1995-03-14
WO1995005173A1 (en) 1995-02-23

Similar Documents

Publication Publication Date Title
AU681672B2 (en) Preparations containing silicon dioxide to improve the taste thereof
US5225197A (en) Pharmaceutical formulation
EP0664697B1 (en) Ranitidine chewable tablets
EP0349103B1 (en) Chewable tablet
US5275823A (en) Pharmaceutical compositions
IE61692B1 (en) Pharmaceutical compositions
US6024987A (en) Pharmaceutical, orally applicable composition
EP1566174A2 (en) Flash-melt oral dosage formulation
JPH05112445A (en) Transfer system that hastens initiation of action and increases latent characteristics
US20070122475A1 (en) Taste masking composition
US5622980A (en) Oral compositions of H2-antagonists
WO1995005173A1 (en) Oral compositions of h2-antagonists
WO1996004888A1 (en) Oral compositions of h2-antagonists
US20040132827A1 (en) Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
JPH07165590A (en) Medicinal composition
IL105870A (en) Pharmaceutical soft capsules containing lysine clonixinate and their preparation
WO1992011003A1 (en) Pharmaceutical compositions
CN1140996A (en) Ranitidine and calcium carbonate pharmaceutical combination product
EP0574624A1 (en) Pharmaceutical compositions
AU2138095A (en) Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960311

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK ES FR GB IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 20001204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010417